Products and Technologies

Adoptive Cell Therapies

Immatics has developed three innovative approaches to producing Adoptive Cell Therapies (ACT): ACTolog®, ACTengine® and ACTallo®. These therapies are directed against targets which will transform the current landscape of tumor therapy.

About ACT

Bispecific T-Cell Receptor Molecules

Immatics' off-the-shelf biotherapeutics leverage the body’s immune system by redirecting and activating the T-cell response towards cancer cells expressing specific tumor targets.

About Bispecific T-Cell receptor molecules

Discovery Platforms

Immatics' XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer. Our powerful TCR discovery technology enables the generation of safer and effective T-cell redirecting products. Together, these platforms allow a full range of cancer therapies to be developed.

About our technologies

Product Pipeline

We have multiple, diverse cancer immunotherapies in our pipeline. These are in clinical and preclinical development directed against a range of cancer targets that have been identified and validated by Immatics’ proprietary XPRESIDENT® platform.

Our pipeline

Our Partners

Amgen

Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies, Jan 09, 2017.

Learn more

MDACC

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies, Aug 26, 2015.

Learn more

MorphoSys

MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology, Aug 25, 2015.

Learn more

Roche

Immatics and Roche sign cancer vaccine and immunotherapy collaboration, Nov 13, 2013.

Learn more

Press Releases

Press release

| USA

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based […]

Read more

Press release

| USA

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine® […]

Read more

Press release

| USA

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with […]

Read more